Failure is an option: learning from unsuccessful proof-of-concept trials

Drug Discovery Today

Volumn 13, Issue 21-22, 2008, Pages 913-916

  Schäfer, Stefan ^a   Kolkhof, Peter ^a  

^a Cardiology Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; CALCIUM; CARIPORIDE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COMPLEMENTARY DNA; CYCLIC GMP; ENIPORIDE; GUANYLATE CYCLASE; ISOSORBIDE DINITRATE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; ORGANIC NITRATE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SODIUM; SODIUM PROTON EXCHANGE PROTEIN 1; TOLVAPTAN; TORCETRAPIB; VASOPRESSIN;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; DATA ANALYSIS; DEATH; DIABETIC NEPHROPATHY; DRUG RESEARCH; DRUG SCREENING; ERECTILE DYSFUNCTION; EXPERIMENTAL MODEL; HEADACHE; HEART FAILURE; HUMAN; HYPONATREMIA; NONHUMAN; PHARMACODYNAMICS; PROOF OF CONCEPT TRIAL; PULMONARY HYPERTENSION; REPEATED DRUG DOSE; SHORT SURVEY; SIDE EFFECT; SPECIES DIFFERENCE; STROKE; SYSTEMATIC ERROR; TACHYPHYLAXIS;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; RESEARCH DESIGN;

EID: 54249107905     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.03.026     Document Type: Short Survey

References (41)

1. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 711-716
2. World Medical Association (2004) Declaration of Helsinki. Ethical principles for medical research involving human subjects. Available at http://www.wma.net/e/policy/pdf/17c.pdf. Assessed May 28, 2008.
3. Altura B., and Altura B. Actions of vasopressin, oxytocin, and synthetic analogs on vascular smooth muscle. Fed. Proc. 43 (1984) 80-86
4. Gavras H., et al. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension 6 (1984) I156-I560
5. Yamamura Y., et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 252 (1991) 572-574
6. Ohnishi A., et al. Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans. J. Clin. Pharmacol. 33 (1993) 230-238
7. Yamada K., et al. Effect of AVP.V1-receptor antagonist on urinary albumin excretion and renal hemodynamics in NIDDM nephropathy: role of AVP.V1-receptor. J. Diabetes Complications 9 (1995) 326-329
8. Nishikawa T., et al. Short-term clinical trial of 1-(1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl)-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Possible effectiveness of the specific vasopressin V1 receptor antagonist for reducing albuminuria in patients with non-insulin dependent diabetes mellitus. Arzneimittelforschung 46 (1996) 875-878
9. Kawano Y., et al. The role of vasopressin in essential hypertension. Plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes. Am. J. Hypertens. 10 (1997) 1240-1244
10. Hirasawa A., et al. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem. Biophys. Res. Commun. 203 (1994) 72-79
11. Serradeil-Le Gal C., et al. Binding of [3H] SR, 49059 a potent nonpeptide vasopressin V1a antagonist to rat and human liver membranes. Biochem. Biophys. Res. Commun. 199 (1994) 353-360
12. Liu J., et al. Human internal mammary artery responses to non-peptide vasopressin antagonists. Clin. Exp. Pharm. Physiol. 21 (1994) 121-124
13. Bax W., et al. [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists. Eur. J. Pharmacol. 285 (1995) 199-202
14. Calò G., et al. Pharmacological characterization of a vasopressin V1 receptor in the isolated human gastric artery. Life Sci. 60 (1997) PL63-68
15. Rosamond W., et al. Heart disease and stroke statistics-2007 update: a report from the american heart association statistics committee and stroke statistics subcommittee. Circulation 115 (2007) 69-171
16. Patel B., et al. Postischemic myocardial 'stunning': a clinically relevant phenomenon. Ann. Intern. Med. 108 (1988) 626-628
17. Rahimtoola S. The hibernating myocardium. Am. Heart J. 117 (1989) 211-221
18. Piper H., et al. The role of Na+/H+ exchange in ischemia-reperfusion. Basic Res. Cardiol. 91 (1996) 191-202
19. Scholz W., et al. Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc. Res. 29 (1995) 260-268
20. Gumina R., et al. A new Na+/H+ exchange (NHE-1) inhibitor, EMD 85131 limits infarct size in dogs when administered prior to or after coronary occlusion. J. Pharmacol. Exp. Ther. (1998) 175-183
21. Knight D., et al. A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J. Pharmacol. Exp. Ther. 297 (2001) 254-259
22. Zeymer U., et al. The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J. Am. Coll. Cardiol. 38 (2001) 1644-1650
23. Linz W., et al. Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642). Clin. Exp. Hypertens. 20 (1998) 733-749
24. Théroux P., et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) investigators. Circulation 102 (2000) 3032-3038
25. Winkelmann B. American heart association scientific sessions. Expert Opin. Investig. Drugs 13 (2004) 435-445
26. Wallis R., et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. 83 (1999) 3C-12C
27. Ghofrani H., et al. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5 (2006) 689-702
28. Przyklenk K., and Kloner R. Sildenafil citrate (vagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J. Am. Coll. Cardiol. 37 (2001) 286-292
29. Ishikura F., et al. Effects of sildenafil citrate (viagra) combined with nitrate on the heart. Circulation 102 (2000) 2516-2521
30. Traverse J., et al. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. Circulation 102 (2000) 2997-3002
31. Campbell S. Science, art and drug discovery: a personal perspective. Clin. Sci. 99 (2000) 255-260
32. Jackson G., et al. Effects of sildenafil citrate on human hemodynamics. Am. J. Cardiol. 83 (1999) 13C-20C
33. Herrmann H., et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N. Engl. J. Med. 342 (2000) 1622-1626
34. Manfroi W., et al. Hemodynamic effects of sildenafil in patients with stable ischemic heart disease. Int. J. Cardiol. 90 (2003) 153-157
35. Arruda-Olson A., et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 287 (2002) 719-725
36. Fox K., et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur. Heart J. 24 (2003) 2206-2212
37. Kling J. From hypertension to angina to viagra. Modern Drug Discov. 1 (1998) 31-38
38. Lindner M.D. Clinical attrition due to biased preclinical assessments of potential efficacy. Pharmacol. Ther. 115 (2007) 148-175
39. Barter P.J., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357 (2007) 2022-2109
40. Forrest M.J., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by an increase in circulating aldosterone levels. Circ. Res. 101 (2007) 1209 (Abstract)
41. Genest J. The yin and yang of high-density lipoprotein cholesterol. J. Am. Coll. Cardiol. 51 (2008) 643-644